Biosimilars in Rheumatoid Arthritis: Current and Emerging Opportunities to Optimize Care

Biosimilars in Rheumatoid Arthritis: Current and Emerging Opportunities to Optimize Care

On-Demand Webcast
Program Details

This webcast is based on live proceedings from a symposium conducted at the 2017 ACR/ARHP annual meeting in San Diego, CA.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.


Gilberto Castañeda-Hernández, MD
Senior Investigator
Department of Pharmacology
Mexico City, Mexico

Daniel Furst, MD
UCLA Department of Medicine
Los Angeles, California

Learning Objectives

After completing this activity, participants should be able to: 

  • Explain the impact of biosimilars on expenditures, accessibility, and the care of patients with rheumatoid arthritis (RA)
  • Describe clinical data required for the approval of biosimilars in RA
  • Highlight recent biosimilar advances, approvals, and data supporting the safety, efficacy, and biosimilarity to respective reference biologics
  • Incorporate new and emerging biosimilars into individualized RA treatment plans
Activity Overview

This on-demand webcast is a simulcast from the live ACR/ARHP lunch symposium on November 8, 2017. 

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10 question post-test with a score of 70% or better, and complete the evaluation form.

After successful completion of the post-test and evaluation form online at, participants may immediately print their documentation of credit.

Release Date: December 11, 2017
Expiration Date: December 11, 2018
Estimated time to complete: 1.0 hour

Participants who completed the live version of this activity are not eligible to receive credit for this enduring material.

For questions regarding this educational activity, please call 609-371-1137.

There is no fee associated with this activity.


In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


NACCME designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 1.0 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour.

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

Independent Clinical Reviewer: Marc D. Cohen, MD, Emeritus Professor of Medicine, Mayo Clinic, Rochester, Minnesota

Planning Committee

The planning committee comprises Gilberto Castañeda-Hernández, MD; Daniel Furst, MD; Susie Seaman, NP; Marc Cohen, MD; and Meaghan Benci, Donna Brophy, Mary Johnson, Susan Kuhn, Randy Robbin, and John Savage, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Castañeda-Hernández: Consultant–Pfizer, Sarofi; Speaker–Abbvie, Novartis, Grunenthal, Pfizer, Roche, Sanofi

Dr. Furst: Consultant–AbbVie, Actelion, Amgen, BMS, Cytori, Novartis, Pfizer, Roche/Genentech; Grant/Research Support: AbbVie, Actelion, Amgen, BMS Corbus,  NIH, Novartis, Pfizer, Roche/Genentech

Ms. Seaman: Advisory Board–MoInlycke Health Care

Ms. Kuhn: Stock (spouse)–Osiris Pharmaceuticals

Dr. Cohen has disclosed no relevant financial relationships with any commercial interest.

Ms. Benci, Ms. Brophy, Ms. Johnson, Mr. Robbin, and Mr. Savage have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

Disclosure of off-label/unapproved uses of drugs and/or devices will be provided prior to the symposium.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity has been supported through independent educational grants from Boehringer Ingelheim and Teva Pharmaceuticals.